Consultation on proposed front-of-package labelling

https://policybase.cma.ca/link/policy13882

POLICY TYPE
Response to consultation

DATE
2018-04-23

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

[Image of document content]

[Text content]

Deborah Kent

April 23, 2018

The Canadian Medical Association (CMA) appreciates the opportunity to participate in the consultation on proposed front-of-package labelling for pharmaceuticals in Canada. CMA is committed to evidence-based recommendations and believes that a regulatory approach should be based on sound scientific and clinical evidence. CMA supports the implementation of a public education strategy to address the issue of over-the-counter (OTC) medication misuse and the abuse of prescribed medications. CMA also supports the development of a comprehensive regulatory framework that addresses the potential harms associated with the misuse of non-prescription drugs.

CMA recommends the following measures:

1. Implement a comprehensive public education strategy to address the issue of over-the-counter (OTC) medication misuse and the abuse of prescribed medications.
2. Develop a regulatory framework that addresses the potential harms associated with the misuse of non-prescription drugs.

CMA looks forward to further discussion and collaboration with stakeholders to ensure that any proposed labelling requirements are effective and evidence-based.

CMA Policybase - Canadian Medical Association